Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for Residual Angina After PCI
NCT03866395Phase 4Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Mar 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivabradine in angina pectoris (2 arms), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoints: Double Product (HR x SBP) at 30 days, Triple Product (HR x SBP x ET) at 30 days and 2 more. Started Mar 2015; status: completed.
02
Drugs
ivabradine
03
Conditions
angina pectoris
Beyond the preview
Go deeper on NCT03866395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866395.